Imrotab 12mg Tablet

Imrotab 12mg tablet is a prescription-based medication. Its active ingredient is Ivermectin (12mg) and belongs to the drug class called antiparasitic (anthelmintic) agents. It is used to treat a variety of parasitic infections in the body such as strongyloidiasis (a roundworm infection) and control onchocerciasis (a worm infection that affects skin and eyes). It works by paralyzing and killing the parasites, allowing the body to eliminate them and thereby control the infection. Correct dosage and duration is administered by the healthcare professional. Always follow the prescription based medication to ensure safe and effective treatment option.

• Treat infections in the intestine and skin

Imrotab 12mg tablet caused side effects that are harmful for the body. Some patients experience mild and some may feel severe side effects. Many of them are resolved on their own and many are treated by proper medical attention. Consult the healthcare professional if any of the symptoms persist:

• Dizziness
• Nausea
• Diarrhea
• Rash/ Itching
• Headache
• Fever
• Swelling of lymph nodes
• Joint or muscle pain
• Orthostatic hypotension

Doctor prescribed Imrotab 12mg tablet on an empty stomach, usually need to take it only once in a day. Try to take it at the fixed time everyday to enhance the effectiveness of the medication. Do not skip or overdose the tablet on the missed as it can increase the risk of side effects. Always the doctor's prescription as recommended to avoid complications during the treatment.

Imrotab 12mg tablet works by targeting the parasites and binding to certain nerve and muscle cells in the parasites in the body. This causes paralysis and death of the cells, leading to its elimination from the human body. However, it does not kill the immature forms (larvae) of some parasites and is therefore mainly effective against adult worms.

• Taylor, H., Gonzales, C., & Duke, B. (1993). Simplified dose schedule of ivermectin. The Lancet, 341(8836), 50-51. https://pubmed.ncbi.nlm.nih.gov/8093293/
• Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., ... & Omilabu, S. (2021). Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM: An International Journal of Medicine, 114(11), 780-788. https://pmc.ncbi.nlm.nih.gov/articles/PMC7928689/
• Johnson-Arbor, K. (2022). Ivermectin: a mini-review. Clinical Toxicology, 60(5), 571-575. https://pubmed.ncbi.nlm.nih.gov/35225114/
• Gardon, J., Boussinesq, M., Kamgno, J., Gardon-Wendel, N., & Duke, B. O. (2002). Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. The Lancet, 360(9328), 203-210. https://pubmed.ncbi.nlm.nih.gov/12133654/
• Schmith, V. D., Zhou, J., & Lohmer, L. R. (2020). The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID‐19. Clinical Pharmacology & Therapeutics, 108(4), 762-765. https://pubmed.ncbi.nlm.nih.gov/32378737/